Physician profile
Charmaine E Earle
NPI 1598833303
$3,077.72
in general payments reported to CMS, 2019-2025
34 companies · $857 in 2025
The $857 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $290 · 2021: $213 · 2022: $98.89 · 2023: $149 · 2024: $561 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,548 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,548.31 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $737.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $482.72 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $246.45 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $175.10 | 2022-2025 | Otezla, Repatha, Krystexxa |
| Amarin Pharma, INC. | $167.52 | 2019-2020 | |
| Lilly USA, LLC | $148.52 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $114.61 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $114.33 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $97.54 | 2023-2025 | |
| Glaxosmithkline, LLC. | $95.52 | 2019-2025 | Trelegy Ellipta |
| Dexcom, INC. | $82.79 | 2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $56.10 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.48 | 2019-2024 | Xifaxan |
| Genzyme Corporation | $39.27 | 2025 | |
| Janssen Pharmaceuticals, INC | $37.41 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.41 | 2019 | |
| Csl Behring | $34.07 | 2024 | Haegarda |
| Paratek Pharmaceuticals, INC. | $32.50 | 2025 | Xhance |
| Merck Sharp & Dohme LLC | $30.94 | 2019 | |
| Boston Scientific Corporation | $30.63 | 2025 | General - Pain Management |
| Abbvie INC. | $29.96 | 2023-2024 | Botox |
| Philips North America LLC | $29.85 | 2019-2025 | Respiratory |
| Insulet Corporation | $23.50 | 2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $22.22 | 2020 | |
| Allergan, INC. | $21.37 | 2020 | |
| Organon LLC | $20.20 | 2025 | Nexplanon |
| Abbott Laboratories | $17.58 | 2019 | |
| Sunovion Pharmaceuticals INC. | $17.53 | 2019 | |
| Mannkind Corporation | $17.48 | 2019 | |
| Qiagen, LLC | $14.68 | 2020 | |
| Shield Therapeutics INC | $14.10 | 2025 | |
| Cequr Corporation | $12.73 | 2024 | Cequr Simplicity |
| Lifescan, INC. | $12.33 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charmaine Earle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.